Bayer/Onyx Pharma’s Nexavar Among MHLW’s Pre-Golden Week Approval Rush
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare's drug approval advisory body, the Pharmaceutical Affairs and Food Sanitization Council's second committee on new drugs April 27 recommended Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) for approval for the additional indication of advanced hepatocellular carcinoma